The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness analysis of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder.
 
Vidit Sharma
No Relationships to Disclose
 
Kevin Wymer
No Relationships to Disclose
 
Christopher Saigal
No Relationships to Disclose
 
Karim Chamie
Consulting or Advisory Role - Urogen pharma
Speakers' Bureau - Urogen pharma
Research Funding - Salix
Other Relationship - Altor BioScience
 
Mark S. Litwin
No Relationships to Disclose
 
Vignesh T. Packiam
No Relationships to Disclose
 
Matthew Mossanen
No Relationships to Disclose
 
Lance C. Pagliaro
Research Funding - Exelixis (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck
 
Bijan J Borah
No Relationships to Disclose
 
Stephen A. Boorjian
Consulting or Advisory Role - ArTara Therapeutics; FerGene; Ferring; Sanofi